证券代码：600774 证券简称：汉商集团 公告编号：2026-008 汉商集团股份有限公司 关于为控股子公司提供担保的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 担保对象及基本情况 | | 本次担保 | | 实际为其提供的 | | 是否在前期 | 本次担保 | | --- | --- | --- | --- | --- | --- | --- | | | 金额 | | 担保余额（不含 | | 预计额度内 | 是否有反 | | | | | 本次担保金额） | | | 担保 | | | 6,000 | 万元 | 4,999.68 | 万元 | 是 | 否 | | 被担保人名称 重庆迪康长江制药 有限公司 | | | | | | | 累计担保情况 | 对外担保逾期的累计金额（万元） | 0 | | --- | --- | | 截至本公告日上市公司及其控股 | 35,439.68 | | 子公司对外担保总额（万元） | | | 对外担保总额占上市公司最近一 期经审计净资产的比例（%） | 21.34 | | ...

证券代码：600774 证券简称：汉商集团 公告编号：2026-007 汉商集团股份有限公司 关于公司以部分自有资产进行抵押贷款 并接受子公司担保的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 汉商集团股份有限公司（以下简称"公司"）于2026年3月获批汉口银行股 份有限公司综合授信1.79亿元，授信敞口1.79亿元，授信期限12个月（以下简 称"本次授信"）。公司将部分自有资产抵押给汉口银行股份有限公司江汉支 行（以下简称"汉口银行"或"乙方"），申请办理本次授信项下流动资金借 款。同时，公司全资子公司成都迪康药业股份有限公司（以下简称"迪康药 业"）为本次授信项下流动资金借款提供连带责任保证。现就相关事宜公告如 下： 一、公司以部分自有资产进行抵押 1.汉阳区汉阳大道139号人信·汉商银座F栋3层，建筑面积5,833.87平方米， 鄂（2021）武汉市汉阳不动产权第0027503号；汉阳区汉阳大道139号人信·汉 商银座F栋2层，建筑面积5,815.22平方米，鄂（2021）武汉市汉阳不动产权第 0027509号。 ...

证券代码：600774 证券简称：汉商集团 公告编号：2026-006 汉商集团股份有限公司 股改限售股上市公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 本次股票上市类型为股改后限售股份；股票认购方式为网下，上市股数为 38,046股。 本次股票上市流通总数为38,046股。 一、股权分置改革方案的相关情况 （一）公司股权分置改革于 2006 年 4 月 28 日经相关股东会议通过，以 2006 年 5 月 19 日作为股权登记日实施，于 2006 年 5 月 23 日实施后首次复牌。 （二）公司股权分置改革方案是否安排追加对价：否 汉商集团非流通股股东承诺将遵守法律、法规和规章的规定，履行法定承诺 义务。此外，公司股东武汉市汉阳区国有资产监督管理办公室（以下简称"区国资 办"）作出如下特别承诺： 1、自股权分置改革方案实施后的首个交易日起，区国资办持有的汉商集团非 流通股份在 36 个月内不通过上海证券交易所挂牌交易出售。 2、如果部分非流通股股东因股权质押、冻结等情况而无法支付相关股东会议 表决 ...

一、上市公司股权分置改革方案的相关情况 1、汉商集团股份有限公司（以下简称"汉商集团"、"上市公司"）股权 分置改革方案于 2006 年 4 月 28 日经相关股东会议通过，以 2006 年 5 月 19 日作 为股权登记日实施，于 2006 年 5 月 23 日实施后首次复牌。 兴业证券股份有限公司关于汉商集团股份有限公司 股改限售流通股上市流通申请的核查意见书 | 保荐机构名称： | 兴业证券股份有限公司 | 上市公司 | A | 股简称： | 汉商集团 | | --- | --- | --- | --- | --- | --- | | 保荐代表人名称： | 盛海涛 | 上市公司 | A | 股代码： | 600774 | 2、汉商集团股权分置改革方案无追加对价安排。 二、上市公司股东在股权分置改革方案中有关承诺的履行情况 汉商集团非流通股股东承诺将遵守法律、法规和规章的规定，履行法定承 诺义务。此外，公司股东武汉市汉阳区国有资产监督管理办公室（以下简称"区 国资办"）作出如下特别承诺： 1、自股权分置改革方案实施后的首个交易日起，区国资办持有的汉商集团 非流通股份在 36 个月内不通过上海证券交易所挂牌 ...

证券代码：600774 证券简称：汉商集团 公告编号：2026-004 汉商集团股份有限公司 关于为控股子公司提供担保的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 累计担保情况 | 对外担保逾期的累计金额（万元） | 0 | | --- | --- | | 截至本公告日上市公司及其控股 | 48,489.49 | | 子公司对外担保总额（万元） | | | 对外担保总额占上市公司最近一 期经审计净资产的比例（%） | 29.20 | | 期经审计净资产 | □担保金额（含本次）超过上市公司最近一 50% □对外担保总额（含本次）超过上市公司最 | | | 近一期经审计净资产 100% | | 特别风险提示（如有请勾选） | □对合并报表外单位担保总额（含本次）达 | | | 到或超过最近一期经审计净资产 30% | | | □本次对资产负债率超过 70%的单位提供担 | | 保 | | | 其他风险提示（如有） | 无 | 一、担保情况概述 （一）担保的基本情况 汉商集团股份有限公司（以下简称"公司" ...

证券代码：600774 证券简称：汉商集团 公告编号：2026-005 汉商集团股份有限公司 关于为控股子公司提供担保的公告 一、担保情况概述 （一）担保的基本情况 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 担保对象及基本情况 | 被担保人名称 | 本次担保 | 实际为其提供的 | | 是否在前期 | 本次担保 | | --- | --- | --- | --- | --- | --- | | | 金额 | 担保余额（不含 | | 预计额度内 | 是否有反 | | | | 本次担保金额） | | | 担保 | | 重庆迪康长江制药 有限公司 | 1,000 万元 | 3,999.68 | 万元 | 是 | 否 | 累计担保情况 | 对外担保逾期的累计金额（万元） | 0 | | --- | --- | | 截至本公告日上市公司及其控股 | 49,489.49 | | 子公司对外担保总额（万元） | | | 对外担保总额占上市公司最近一 期经审计净资产的比例（%） | 29.80 | | 期经审计净资产 | ...

Group 1 - The stock price of Hanchang Group (600774) has shown relatively stable fluctuations over the past week, with a range of -0.10% and an amplitude of 4.68%. The closing price on February 13, 2026, was 9.82 yuan, with a single-day increase of 0.51% and a trading volume of 51.65 million yuan, indicating low short-term capital participation as the main capital outflow was 4.38 million yuan [1] - On February 9, 2026, a national drug procurement bidding was held, involving 316 types of chemical drugs, which may impact pricing and sales expectations in the pharmaceutical sector. Hanchang Group's main business includes chemical drug formulations, accounting for 47.74% of its operations [2] - According to the Q3 2025 financial report, Hanchang Group achieved an operating income of 764 million yuan from January to September 2025, a year-on-year decrease of 15.49%. However, the net profit attributable to shareholders increased significantly by 274.07% to 9.33 million yuan, mainly due to cost control and improvements in non-recurring income, although the overall profitability remains under pressure with a negative price-to-earnings ratio [3] Group 2 - Institutional attention towards Hanchang Group is low, with the latest sentiment being neutral and no recent research records. All institutional ratings are neutral, with no clear target price or profit forecast adjustments, indicating a lack of short-term expectations from the market [4]

Core Viewpoint - Han Commercial Group Co., Ltd. is expected to report a net loss for the year 2025, continuing its trend of negative profitability from the previous year [2][3]. Group 1: Performance Forecast - The company anticipates a net profit attributable to shareholders of the parent company in the range of -90 million to -60 million yuan for the year 2025 [2][3]. - The expected net profit, excluding non-recurring gains and losses, is projected to be between -49.98 million and -19.98 million yuan [4]. Group 2: Previous Year’s Performance - In the previous year, the total profit was -5.4686 million yuan, with a net profit attributable to shareholders of the parent company at -14.5872 million yuan [6]. - The net profit attributable to shareholders, excluding non-recurring gains and losses, was -38.0898 million yuan [6]. Group 3: Reasons for Expected Loss - The primary reason for the anticipated loss in 2025 is the planned impairment of goodwill related to the Wuhan Huake Reproductive Obstetrics Hospital asset group, estimated to be between 80 million and 90 million yuan [8]. - This non-cash impairment is expected to significantly impact the company's net profit for the year [8].

Core Viewpoint - The company, Han Commercial Group Co., Ltd., anticipates a continued loss for the fiscal year 2025, projecting a net profit attributable to shareholders of between -90 million and -60 million yuan, indicating a worsening financial situation compared to the previous year [2][3]. Group 1: Performance Forecast - The performance forecast period is from January 1, 2025, to December 31, 2025 [3]. - The company expects a net profit attributable to shareholders of between -90 million and -60 million yuan for 2025, continuing the trend of losses from the previous year [2][3]. - The projected net profit, excluding non-recurring gains and losses, is estimated to be between -49.98 million and -19.98 million yuan [4]. Group 2: Previous Year’s Financial Performance - In the previous year, the total profit was -5.4686 million yuan, with a net profit attributable to shareholders of -14.5872 million yuan [6]. - The net profit attributable to shareholders, excluding non-recurring gains and losses, was -38.0898 million yuan [6]. - The earnings per share for the previous year were -0.0494 yuan [7]. Group 3: Reasons for Expected Loss - The company adheres to the "Enterprise Accounting Standards" and related accounting policies, conducting year-end impairment tests on relevant assets [8]. - A significant factor contributing to the expected loss for 2025 is the planned goodwill impairment related to the Wuhan Huake Reproductive Obstetrics Hospital asset group, estimated between 80 million and 90 million yuan [8]. - The final amount of goodwill impairment will be determined by the evaluation and audit conducted by the company's appointed assessment and audit institutions [8].

Core Viewpoint - Han Commercial Group (600774.SH) is expected to continue incurring losses in 2025, with projected net profit attributable to shareholders ranging from -90 million to -60 million yuan compared to the previous year [1] Financial Performance - The company anticipates a net profit attributable to shareholders, excluding non-recurring gains and losses, to be between -49.98 million and -19.98 million yuan for the year 2025 [1]